Tarsus Pharmaceuticals Beheer
Beheer criteriumcontroles 4/4
De CEO Tarsus Pharmaceuticals is Bobby Azamian, benoemd in Nov2016, heeft een ambtstermijn van 7.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.13M, bestaande uit 19.8% salaris en 80.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.24% van de aandelen van het bedrijf, ter waarde $ 41.32M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 4.1 jaar.
Belangrijke informatie
Bobby Azamian
Algemeen directeur
US$3.1m
Totale compensatie
| Percentage CEO-salaris | 19.8% |
| Dienstverband CEO | 8yrs |
| Eigendom CEO | 2.2% |
| Management gemiddelde ambtstermijn | 3.5yrs |
| Gemiddelde ambtstermijn bestuur | 4.1yrs |
Recente managementupdates
Recent updates
US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results
Nov 16
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%
Nov 07Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money
Nov 05Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable
Sep 05Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
Aug 20With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For
Jun 26Following Up On Tarsus Pharmaceuticals
May 28Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
May 11Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
Mar 08Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic
Mar 03Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 01Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Nov 12What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates
Aug 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$134m |
| Jun 30 2024 | n/a | n/a | -US$150m |
| Mar 31 2024 | n/a | n/a | -US$148m |
| Dec 31 2023 | US$3m | US$620k | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$108m |
| Jun 30 2023 | n/a | n/a | -US$91m |
| Mar 31 2023 | n/a | n/a | -US$65m |
| Dec 31 2022 | US$4m | US$590k | -US$62m |
| Sep 30 2022 | n/a | n/a | -US$63m |
| Jun 30 2022 | n/a | n/a | -US$56m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$7m | US$550k | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$3m | US$437k | -US$27m |
| Sep 30 2020 | n/a | n/a | -US$17m |
| Jun 30 2020 | n/a | n/a | -US$7m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$416k | US$300k | -US$5m |
Compensatie versus markt: De totale vergoeding ($USD 3.13M ) Bobby } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.50M ).
Compensatie versus inkomsten: De vergoeding van Bobby is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Bobby Azamian
8yrs
Tenure
US$3,130,332
Compensatie
Dr. Bobak R. Azamian, also known as Bobby, MD, Ph D, DPhil, is Co-Founder of Tarsus Pharmaceuticals, Inc. and serves as its President since November 2016. He serves as Chief Executive Officer at Tarsus Pha...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 8yrs | US$3.13m | 2.24% $ 41.3m | |
| CFO & Chief Strategy Officer | 1.6yrs | US$3.99m | 0.047% $ 874.8k | |
| Chief Operating Officer | 4.3yrs | US$1.74m | 0.17% $ 3.1m | |
| Chief Medical Officer | 4.3yrs | US$180.21k | 0.087% $ 1.6m | |
| Head of Investor Relations | 3.2yrs | geen gegevens | geen gegevens | |
| General Counsel & Corporate Secretary | 3.8yrs | US$2.53m | 0.11% $ 2.0m | |
| Senior Director of Corporate Communications | 2.6yrs | geen gegevens | geen gegevens | |
| Vice President of Marketing | 2.8yrs | geen gegevens | geen gegevens | |
| Vice President of Sales | 2.7yrs | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 3.8yrs | US$3.21m | 0.089% $ 1.6m | |
| Chief Commercial Officer | 4.3yrs | geen gegevens | 0.14% $ 2.6m | |
| Senior Vice President of Corporate Affairs | 1.1yrs | geen gegevens | geen gegevens |
3.5yrs
Gemiddelde duur
46yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TARS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 7.9yrs | US$3.13m | 2.24% $ 41.3m | |
| Independent Director | 7.8yrs | US$183.33k | 0.46% $ 8.6m | |
| Lead Independent Director | 4yrs | US$265.83k | 0.027% $ 499.4k | |
| Independent Director | 4.9yrs | US$178.58k | 0.014% $ 258.2k | |
| Independent Director | 2.1yrs | US$186.46k | 0.016% $ 290.3k | |
| Independent Director | 3.3yrs | US$183.71k | 0.014% $ 258.2k | |
| Independent Director | 4.3yrs | US$171.71k | 0.017% $ 306.3k | |
| Director | no data | geen gegevens | geen gegevens |
4.1yrs
Gemiddelde duur
67.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TARS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).